The specter of generic challenges has repeatedly loomed above copyright’s iconic drug, PDE5 Inhibitor, raising questions about the prospects of similar pharmaceutical portfolios. While early years saw impressive returns, the intellectual property expiration has allowed the path for discounted substitutes, potentially reducing earnings and posing